Table 1.

Correlation of positive and negative expressions of JAK2, STAT3 and VEGF with clinicopathologic characteristics of NPC

Clinicopathologic characteristics	Case	JAK2		χ2	P	STAT3		χ2	P	VEGF		χ2	P
		Positive	Negative			Positive	Negative			Positive	Negative
Gender
Male	62	38	24	0.295	0.587	44	18	0.220	0.639	44	18	5.459	0.622
Female	41	24	17			29	12			37	4
Age (year)
< 50	47	32	15	0.274	0.600	34	13	1.862	0.172	36	11	1.026	0.311
≥ 50	56	30	26			39	17			45	11
T stage
T1-2	22	12	10	0.373	0.042	11	11	3.311	0.015	15	7	1.822	0.002
T3-4	81	50	31			62	19			66	15
LNM
Yes	60	41	19	3.974	0.046	48	12	0.421	0.016	51	9	3.460	0.043
No	43	21	22			25	18			30	13
N stage
N0	28	13	15	0.704	0.015	25	3	0.317	0.033	26	2	4.627	0.031
N1-3	75	49	26			48	27			55	20
Differentiation type
Differentiated	72	46	26	1.363	0.243	50	22	0.211	0.646	56	16	0.039	0.843
Undifferentiated	31	16	15			23	8			25	6
Clinical stage
I–II	48	22	26	5.655	0.017	29	19	0.771	0.038	29	19	13.942	<0.001
III–IV	55	40	15			44	11			52	3
Smoking history
Yes	32	23	9	0.571	0.450	25	7	4.099	0.053	27	5	0.909	0.340
No	71	39	32			48	23			54	17
Family history
Yes	19	11	8	0.051	0.821	13	6	0.672	0.412	14	5	1.449	0.229
No	84	51	33			60	24			67	17

NPC nasopharyngeal carcinoma, LNM lymph node metastasis, JAK2 Janus kinase 2, STAT3 Signal transducer and activator of transcription-3, VEGF Vascular endothelial growth factor, T stage, lymph node metastasis, N stage and clinical stage, all P < 0.05